Skip to main content
×
Home

Long-acting injectable antipsychotics: shall the last be first?

Abstract

ISSUE:A paradigm shift is afoot in which the “last shall be first,” namely, use of long-acting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia, may be shifting to first-line treatment of early episodes of this illness.

Copyright
References
Hide All
1. Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 5th ed. Cambridge, UK: Cambridge University Press; 2014.
2. Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013; 13(7): 767783.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10): 892909.
4. Shi L, Ascher-Svanum H, Zhu B, etal. Characteristics and use patterns of patients taking first generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007; 58(4): 482488.
5. Munk-Jorgensen P, Nielsen J, Nielsen RE, Stahl SM. Last episode psychosis. Acta Psychiatr Scand. 2009; 119(6): 417418.
6. Morrisette DA, Stahl SM. Optimizing outcomes in schizophrenia: long acting depots and long term treatment. CNS Spectr. 2012; 17(Suppl 1): 1021.
7. Morrissette DA, Stahl SM. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatric Practice. Dordrecht, NL: Springer. Vol. I; 2012: 107125.
8. van Haren NE, Hulshoff Pol HE, Schnack HG, etal. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007; 32(10): 20572066.
9. Stahl SM. Stahl;s Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
10. Agid O, Arenovich T, Sajeev G, etal. An algorithm-based approach to first episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72(11): 14391444.
11. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957965.
12. Tiihonen J, Haukka J, Taylor M, etal. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6): 603609.
13. Rosenheck RA, Krystal JH, Lew R, etal. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011; 364(9): 842851.
14. Subotnik KL, Nuechterlein KH, Ventura J, etal. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011; 168(3): 286292.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 8
Total number of PDF views: 83 *
Loading metrics...

Abstract views

Total abstract views: 547 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 11th December 2017. This data will be updated every 24 hours.